home / stock / govxw / govxw news

GOVXW News and Press, GeoVax Labs Inc. Warrants From 05/04/23

Stock Information
Company Name: GeoVax Labs Inc. Warrants
Stock Symbol: GOVXW
Market: NASDAQ
Website: geovax.com
Menu
GOVXW GOVXW Quote GOVXW Short GOVXW News GOVXW Articles GOVXW Message Board
Get GOVXW Alerts

News, Short Squeeze, Breakout and More Instantly...
GOVXW - GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

Cancer Gene Therapy Program and Next-Generation COVID-19 Vaccine Advancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30 p.m. ET ATLANTA, GA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire ...
GOVXW - GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host

ATLANTA, GA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on...

GOVXW - GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023

ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report first quarter 2023 financial r...

GOVXW - GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses

Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infec...
GOVXW - GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunother...

GOVXW - GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model Atlanta, GA, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disease...

GOVXW - GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

New data from the ongoing Phase 2 trial of GEO-CM04S1 to be presented Atlanta, GA, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases...
GOVXW - GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

Company Expands Ongoing Clinical Trials and the Breadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA, March 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vacci...

GOVXW - GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated for Best Academic/Research Team Award ATLANTA, GA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines ...

GOVXW - GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and in...
Previous 10 Next 10